Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 10/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13836585 | 0.89 | P4HB (0.83) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL15781888 | 0.88 | MDM2 (0.81) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL15783146 | 0.88 | P4HB (1.00) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL15783172 | 0.88 | P4HB (0.81) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL15783114 | 0.88 | P4HB (1.00) | P4HBMDM2MAPTKDM4ETDP1 | |
| SCHEMBL2153186 | 0.87 | MDM2 (0.80) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL2153101 | 0.87 | P4HB (0.77) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL13836021 | 0.86 | P4HB (0.78) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL13836595 | 0.85 | MAPT (0.85) | P4HBMDM2MAPTKDM4EALDH1A1 | |
| SCHEMBL13836063 | 0.85 | MAPT (0.91) | P4HBMDM2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | P4HB 590/4885MDM2 3001/4885MAPT 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.